RecruitingPhase 2NCT06807593
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Sponsor
M.D. Anderson Cancer Center
Enrollment
10 participants
Start Date
Feb 24, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Ustekinumab for people with cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGUstekinumab
Given by infusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06807593
Related Trials
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
NCT069702754 locations
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
NCT055615951 location
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
NCT064580365 locations
Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors
NCT066343813 locations
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT0591926433 locations